There is a pressing need to investigate anti-inflammatory and cardiorenal properties of GLP-1 RA in tumor-bearing models treated with highly cardiotoxic therapies (i.e., anthracyclines at total cumulative dose ≥ 400 mg/m2 alone or associated with radiotherapy or HER-2 blocking agents). This evidence concerns the gene ERBB2 and neoplasm.